Eylea (aflibercept)

Eylea (aflibercept) is authorized only for listed FDA‑approved ophthalmic indications — neovascular (wet) AMD, macular edema following RVO, DME, DR — and selected compendial off‑label neovascular ophthalmic uses; uses outside those listed are not covered. Approval is for 12 months and requires the diagnosis to match a listed indication, administration by or under an ophthalmologist’s supervision, submission of clinical documentation, and adherence to dosing guidance (AMD: 2 mg intravitreal q4 weeks ×3 then q8w; RVO: 2 mg q4w; DME/DR: recommended 2 mg q4w per source text).

"Neovascular (wet) age-related macular degeneration (AMD)"

Sign up to see full coverage criteria, indications, and limitations.